



RNS Number : 7255B  
Roquefort Therapeutics PLC  
06 June 2023

6 June 2023

**Roquefort Therapeutics plc**  
("Roquefort Therapeutics" or the "Company")

**Notice of Annual General Meeting**

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, has today posted its Notice of Annual General Meeting to Shareholders. The Annual General Meeting is scheduled to take place at the offices of Axiom Ince Limited, Aldgate Tower, 2 Leman Street, London E1 8QN at 9.00 am on 29 June 2023.

The Notice of Annual General Meeting and Forms of Proxy can be downloaded from the Company's corporate website at:  
<https://www.roquefortplc.com/shareholder-documents>

**-ENDS-**

**Enquiries:**

**Roquefort Therapeutics plc**

Stephen West (Chairman) / Ajan Reginald (CEO)	+44 (0)20 3290 9339
--	------------------------

**Hybridan LLP (Joint Broker)**

Claire Louise Noyce	+44 (0)203 764 2341
---------------------	------------------------

**Optiva Securities Limited (Joint Broker)**

Christian Dennis	+44 (0)20 3411 1881
------------------	------------------------

**Buchanan (Public Relations)**

Ben Romney / Jamie Hooper / George Beale	+44 (0)20 7466 5000
--	------------------------

LEI: 254900P4SISIWOR9RH34

**About Roquefort Therapeutics**

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology

segment prior to partnering or selling to big pharma.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lynamid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Roquefort Therapeutics' portfolio consists of five fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- Midkine mRNA therapeutics with novel anti-cancer approach;
- STAT-6 siRNA therapeutics targeting solid tumours with significant *in vivo* efficacy; and
- MK cell therapy with direct and NK-mediated anti-cancer action

For further information on Roquefort Therapeutics, please visit [www.roquefortplc.com](http://www.roquefortplc.com) and @RoquefortTherap on Twitter.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOANKPBQDBKBF

Anonymous (not verified)

Notice of Annual General Meeting

33550429

A

Tue, 06/06/2023 - 07:00

LSE RNS

Results and Trading Reports

ROQ